Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03665441
Title Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ERYtech Pharma

pancreatic adenocarcinoma


Eryaspase + Gemcitabine + Nab-paclitaxel

Eryaspase + Fluorouracil + Irinotecan + Leucovorin

Fluorouracil + Irinotecan + Leucovorin

Gemcitabine + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA | FRA

No variant requirements are available.